v. 4, n. 78, 2024

International Journal of Health Science

NEUROIMAGING IN THE DETECTION OF ENDOCRINE DYSFUNCTION FOLLOWING TRAUMATIC BRAIN INJURY: A COMPREHENSIVE REVIEW

Leonardo Lucas Pereira Filho
http://lattes.cnpq.br/4022430994941735

Vinicius Louza Garcia
https://lattes.cnpq.br/0753056509195919

Nara Fernanda Alencar da Costa Pinheiro
http://lattes.cnpq.br/6493513370859829

Isabela Massarotti
https://lattes.cnpq.br/0011411041304167

Caio Pedral Sampaio Sgarbi

Maykon Pablo Aguiar Fenelon
http://lattes.cnpq.br/521999614166349

Paula Cristina de Melo Santos
https://lattes.cnpq.br/9974617154517897

Helder Barbosa Rodrigues

Enzo Salles Fatuch

Victor Joaquim de Amaral e Gouveia
http://lattes.cnpq.br/6137327346648792

Giovana Pivelli Usberco

Clarice Lima Machado
http://lattes.cnpq.br/0167523429442434

Mauricio Lopes da Silva Netto
http://lattes.cnpq.br/4791743372358340

Abstract: INTRODUCTION Traumatic brain injury (TBI) is a major global health issue, leading to significant morbidity and mortality. Beyond the immediate cognitive and motor impairments, TBI is often associated with endocrine dysfunctions, particularly hypopituitarism, which is frequently underdiagnosed. The pituitary gland, due to its anatomical location and vulnerability to injury, is often affected post-TBI. The introduction discusses the importance of neuroimaging techniques, such as MRI and CT, in the early detection and management of pituitary dysfunction. It highlights the need for advanced imaging modalities to improve diagnostic accuracy and patient outcomes. **OBJETIVE** To evaluate the role of neuroimaging techniques in the detection and management of endocrine dysfunctions, particularly pituitary insufficiency, following traumatic brain injury (TBI). **METHODS** This is a narrative review which included studies in the MEDLINE – PubMed (National Library of Medicine, National Institutes of Health), COCHRANE, EMBASE and Google Scholar databases, using as descriptors: "Traumatic Brain Injury" AND "Neuroimaging Techniques" AND "Pituitary Dysfunction" OR "Hypopituitarism" AND "Endocrine Dysfunction" in the last years. **RESULTS AND DISCUSSION** The results section delves into the prevalence of endocrine dysfunctions in TBI patients, particularly focusing on pituitary insufficiency. It reviews various neuroimaging techniques, including MRI, CT, and emerging functional imaging modalities like fMRI and PET, assessing their efficacy in detecting pituitary abnormalities. The discussion also explores the timing of imaging, the correlation between imaging findings and hormonal assays, and the role of neuroimaging in differentiating primary from secondary pituitary dysfunction. The challenges of using these techniques in

clinical practice, including cost, variability in protocols, and ethical considerations, are also addressed. **CONCLUSION** The conclusion emphasizes the critical role of neuroimaging in the early detection and management of endocrine dysfunctions following TBI. While advances in imaging technology have improved diagnostic capabilities, challenges remain in standardizing protocols and integrating these techniques into routine clinical practice. The need for interdisciplinary collaboration, further research, and the development of guidelines to optimize the use of neuroimaging in managing TBI-related endocrine dysfunctions is highlighted. The future of neuroimaging in this context looks promising, with potential benefits for improving long-term outcomes in TBI survivors.
Keywords: Traumatic Brain Injury (TBI); Pituitary Dysfunction; Neuroimaging; Endocrine Dysfunction.

INTRODUCTION

Traumatic brain injury (TBI) remains one of the leading causes of morbidity and mortality worldwide, affecting millions of individuals annually[1]. The consequences of TBI extend beyond the immediate cognitive and motor dysfunctions observed post-injury, encompassing a diverse range of systemic complications, with endocrine dysfunctions being one of the most underrecognized yet clinically significant[1]. Post-TBI endocrine dysfunction, particularly pituitary insufficiency, has garnered increasing attention in the medical literature due to its long-term implications for patient quality of life[1]. These dysfunctions often go undiagnosed, which can exacerbate the clinical picture, increase the risk of additional complications, and impair the rehabilitation process[2].

The pathophysiology of TBI is complex and multifaceted, involving both primary and secondary mechanisms of injury[2]. While the primary injury results from the immediate impact, secondary injury is driven by a cascade of biochemical and cellular events that evolve over time, leading to progressive neuronal damage[2]. This secondary injury cascade is closely linked to the development of endocrine dysfunction, particularly within the hypothalamic-pituitary axis[2]. The pituitary gland, situated at the base of the brain, is especially vulnerable to damage following TBI due to its anatomical location and unique vascular supply[3]. The mechanisms underlying pituitary dysfunction post-TBI include direct trauma, vascular injury, and neuroinflammatory processes, all of which can impair the gland's function[3].

Despite the clinical significance of endocrine dysfunctions after TBI, these complications are often underdiagnosed[3]. Pituitary insufficiency, in particular, can present with a broad spectrum of symptoms that are frequently nonspecific, such as fatigue, weight gain, and depression[3]. This underrecognition underscores the critical need for early and accurate detection of pituitary dysfunction in TBI patients, which is where neuroimaging plays a pivotal role[4]. Historically, the diagnosis of pituitary dysfunction relied heavily on clinical evaluation and hormonal assays[4]. However, advancements in neuroimaging techniques have revolutionized our ability to visualize the hypothalamic-pituitary axis and detect structural abnormalities that may indicate dysfunction[4].

Neuroimaging has become an indispensable tool in the evaluation of patients with TBI, providing crucial insights into the extent of injury and the potential for endocrine sequelae[5]. The evolution of imaging modalities, from traditional computed tomography (CT) to advanced magnetic resonance imaging (MRI) techniques, has enhanced our capacity to identify subtle changes in

pituitary morphology and function[5]. The role of neuroimaging in detecting pituitary dysfunction is further supported by its ability to correlate imaging findings with clinical outcomes, thereby aiding in the early identification and management of endocrine complications[5].

The application of neuroimaging in TBI, however, is not without its challenges[6]. Variability in imaging protocols, differences in the sensitivity and specificity of various techniques, and the need for interdisciplinary collaboration all pose significant obstacles to the widespread implementation of neuroimaging in this context[6]. Nevertheless, the integration of neuroimaging into the diagnostic pathway for TBI-related endocrine dysfunction holds promise for improving patient outcomes, particularly through the early detection of pituitary insufficiency[6].

As the field of neuroimaging continues to advance, new techniques and technologies are emerging that have the potential to further refine our understanding of the relationship between TBI and endocrine dysfunction[7]. Functional imaging modalities, such as functional MRI (fMRI) and positron emission tomography (PET), offer the possibility of assessing not only structural abnormalities but also functional impairments within the hypothalamic-pituitary axis[7]. These developments highlight the importance of continued research into the use of neuroimaging for the detection and management of endocrine dysfunctions in TBI patients[7].

OBJETIVES

To evaluate the role of neuroimaging techniques in the detection and management of endocrine dysfunctions, particularly pituitary insufficiency, following traumatic brain injury (TBI).

SECUNDARY OBJETIVES

- To analyze the correlation between neuroimaging findings and clinical manifestations of endocrine dysfunction in TBI patients.
- To explore the emerging trends and advancements in neuroimaging that have the potential to improve early diagnosis and management of endocrine complications in TBI survivors.
- To assess the prevalence and types of endocrine dysfunctions in TBI patients through neuroimaging studies.

METHODS

This is a narrative review, in which the main aspects of the role of neuroimaging techniques in the detection and management of endocrine dysfunctions, particularly pituitary insufficiency in recent years were analyzed. The beginning of the study was carried out with theoretical training using the following databases: PubMed, sciELO and Medline, using as descriptors: “Traumatic Brain Injury” AND “Neuroimaging Techniques” AND “Pituitary Dysfunction” OR “Hypopituitarism” AND “Endocrine Dysfunction” in the last years. As it is a narrative review, this study does not have any risks.

Databases: This review included studies in the MEDLINE – PubMed (National Library of Medicine, National Institutes of Health), COCHRANE, EMBASE and Google Scholar databases.

The inclusion criteria applied in the analytical review were human intervention studies, experimental studies, cohort studies, case-control studies, cross-sectional studies and literature reviews, editorials, case reports, and poster presentations. Also, only studies writing in English and Portuguese were included.

RESULTS AND DISCUSSION

In recent years, there has been a significant increase in the recognition of endocrine dysfunctions as a common sequela of traumatic brain injury[9]. Among the most prevalent of these dysfunctions is pituitary insufficiency, which can manifest as deficiencies in one or more pituitary hormones[9]. The reported prevalence of pituitary dysfunction in TBI patients varies widely, with estimates ranging from 15% to 68%, depending on the study population, time of assessment post-injury, and diagnostic criteria used[9]. This wide range underscores the need for standardized diagnostic approaches and highlights the role of neuroimaging in early and accurate detection[10].

Magnetic resonance imaging (MRI) has emerged as the gold standard in the evaluation of pituitary gland abnormalities in TBI patients[10]. MRI provides detailed visualization of the hypothalamic-pituitary axis, allowing for the identification of structural changes such as pituitary atrophy, hemorrhage, and empty sella syndrome[10]. These imaging findings have been correlated with clinical symptoms and hormonal profiles, aiding in the diagnosis of pituitary dysfunction[11]. For example, pituitary atrophy detected on MRI has been associated with deficiencies in growth hormone and gonadotropins, while pituitary hemorrhage is often linked to acute adrenal insufficiency[11]. However, the sensitivity of MRI in detecting pituitary dysfunction is not absolute, and normal imaging does not exclude the presence of hormonal deficiencies, particularly in the early stages post-TBI[11].

Computed tomography (CT) scans, although less sensitive than MRI, continue to play a role in the initial assessment of TBI, particularly in the acute setting[12]. CT is highly effective in detecting acute hemorrhages, fractures, and other traumatic lesions that may indirectly affect pituitary function[12]. However, its utility in the specific evaluation of the pituitary gland is limited due to lower resolution and contrast sensitivity compared to MRI[12]. Nevertheless, CT remains an important tool in the comprehensive evaluation of TBI patients, particularly when MRI is contraindicated or unavailable[13].

Recent advancements in neuroimaging have introduced functional imaging modalities that offer insights into the metabolic and functional status of the hypothalamic-pituitary axis[13]. Functional MRI (fMRI) and positron emission tomography (PET) have been explored as tools for assessing hypothalamic function and detecting subtle changes that may precede overt structural abnormalities[13]. fMRI, for instance, can detect changes in blood flow and oxygenation in response to neuroendocrine stimuli, providing a functional assessment of the hypothalamic-pituitary axis[14]. PET imaging, particularly when combined with specific tracers, can assess metabolic activity and receptor binding within the pituitary gland, offering potential for early detection of endocrine dysfunction[14].

The timing of neuroimaging is critical in the detection of endocrine dysfunctions post-TBI[14]. Early imaging, particularly within the first few weeks post-injury, can identify acute changes such as hemorrhage or edema that may impact pituitary function[15]. However, delayed imaging, performed several months to years post-injury, may be necessary to detect chronic changes such as pituitary atrophy or empty sella syndrome[15]. Longitudinal imaging studies have demonstrated that some patients with initially normal imaging may develop pituitary abnormalities over time, highlighting the need for ongoing monitoring in TBI patients at risk for endocrine dysfunction[15].

The role of neuroimaging in differentiating primary from secondary endocrine dysfunctions is also of clinical importance[16]. Primary

pituitary dysfunction arises from direct damage to the pituitary gland, while secondary dysfunction results from hypothalamic injury or disruption of the pituitary stalk[16]. Neuroimaging can help distinguish between these two etiologies by assessing the integrity of the hypothalamic-pituitary axis and identifying specific patterns of injury[16]. For example, damage to the pituitary stalk seen on MRI may indicate secondary hypopituitarism due to hypothalamic injury, while primary hypopituitarism is more likely associated with intrinsic pituitary abnormalities[17].

Despite the advances in neuroimaging, several challenges remain in the diagnosis and management of endocrine dysfunctions post-TBI[17]. Variability in imaging protocols, differences in the interpretation of imaging findings, and the lack of standardized criteria for diagnosing pituitary dysfunction all contribute to inconsistencies in clinical practice[17]. Moreover, the cost and availability of advanced imaging techniques such as fMRI and PET limit their widespread use, particularly in resource-limited settings[18]. The clinical relevance of imaging findings must also be carefully considered in the context of each patient's overall clinical picture[18]. While neuroimaging can provide valuable information about the structural and functional status of the hypothalamic-pituitary axis, it should not be the sole determinant of diagnosis[18]. Hormonal assays remain essential in confirming endocrine dysfunction and guiding treatment decisions[19]. Imaging findings should be integrated with clinical and laboratory data to ensure accurate diagnosis and appropriate management[19].

In addition to its diagnostic role, neuroimaging has implications for the long-term management of TBI patients[19]. Imaging can help monitor the progression of endocrine dysfunctions over time, assess the response to treatment, and identify patients at risk for further complications[20]. For instance, follow-up MRI studies can track changes in pituitary volume, providing insights into the long-term effects of TBI on the hypothalamic-pituitary axis[20]. Such information is critical for tailoring treatment plans and optimizing patient outcomes[20]. Furthermore, neuroimaging has the potential to enhance our understanding of the pathophysiology of endocrine dysfunctions in TBI[21]. By correlating imaging findings with clinical and hormonal data, researchers can gain insights into the mechanisms underlying pituitary damage and identify potential targets for therapeutic intervention[21]. This knowledge could lead to the development of new strategies for preventing and treating endocrine dysfunctions in TBI patients[21].

As research in this field continues to evolve, there is a growing recognition of the need for interdisciplinary collaboration in the management of TBI-related endocrine issues[22]. Endocrinologists, neurologists, neurosurgeons, and radiologists must work together to develop standardized protocols for the diagnosis and treatment of pituitary dysfunction in TBI patients[22]. Such collaboration ensures that all aspects of care are addressed comprehensively and that patients receive the most appropriate and effective interventions[22].

Emerging trends in neuroimaging offer promising avenues for further enhancing the detection and management of endocrine dysfunction in TBI patients[23]. Techniques such as diffusion tensor imaging (DTI) and advanced MRI protocols like susceptibility-weighted imaging (SWI) and arterial spin labeling (ASL) are being investigated for their potential to provide more detailed assessments of brain injury[23]. These imaging modalities could help identify microstructural changes and alterations in cerebral blood flow that may influence pituitary function[23]. These techniques could help identify patients at risk for developing endocrine dysfunctions earlier in

the course of their disease, potentially before clinical symptoms become apparent[24].

The exploration of multimodal imaging approaches, which combine structural, functional, and metabolic imaging, is also an area of active research[24]. For example, combining fMRI with DTI could offer insights into the connectivity of the hypothalamic-pituitary axis and how this network is disrupted in TBI[24]. Similarly, integrating PET imaging with MRI could provide both structural and metabolic information, giving a more comprehensive view of pituitary function and its disturbances[25]. These advances highlight the potential for neuroimaging to move beyond merely identifying structural abnormalities to offering a more dynamic understanding of pituitary dysfunctions[25].

In pediatric patients with TBI, the application of neuroimaging for detecting endocrine dysfunction presents unique challenges and opportunities[25]. The developing brain and endocrine system in children require careful consideration when interpreting imaging findings[26]. Growth hormone deficiency, for example, is a common sequela of TBI in children and can have profound effects on development if not diagnosed and treated early[26]. Pediatric-specific imaging protocols and longitudinal studies are needed to better understand how TBI affects the hypothalamic-pituitary axis in this population and to develop age-appropriate diagnostic and therapeutic strategies[26].

Cost-effectiveness remains a significant consideration in the widespread implementation of advanced neuroimaging techniques[27]. While the potential benefits of early and accurate detection of endocrine dysfunctions are clear, the high costs associated with techniques like fMRI and PET limit their accessibility, particularly in resource-constrained settings[27]. Cost-benefit analyses are necessary to determine the most effective use of these technologies in different healthcare environments and to identify which patient populations are most likely to benefit from advanced imaging[27].

Moreover, the ethical considerations surrounding the use of neuroimaging in TBI-related endocrine dysfunction cannot be overlooked[28]. Issues such as patient consent, the potential for overdiagnosis, and the implications of incidental findings must be carefully navigated[28]. As neuroimaging technologies become more sophisticated, the ability to detect subtle abnormalities increases, raising questions about how to interpret and act on these findings[28]. Clinicians must balance the need for thorough investigation with the risks of unnecessary interventions and the psychological impact of ambiguous results on patients[29].

Long-term outcomes for TBI patients with endocrine dysfunction are influenced by the timing and accuracy of diagnosis, the appropriateness of treatment, and the ability to monitor and adjust care over time[29]. Neuroimaging plays a critical role in each of these aspects, from the initial detection of dysfunction to ongoing management and follow-up[29]. The ability to track changes in the hypothalamic-pituitary axis over time, and to correlate these with clinical and hormonal outcomes, provides valuable information that can guide therapeutic decisions and improve patient prognoses[30].

The future directions of research in neuroimaging and endocrine dysfunction in TBI are likely to focus on refining these techniques, exploring their integration with other diagnostic modalities, and developing evidence-based guidelines for their use in clinical practice[30]. As our understanding of the neuroendocrine consequences of TBI deepens, so too will the potential for neuroimaging to contribute to better patient outcomes[30]. Continued investment in

research, technology, and interdisciplinary collaboration will be essential to realizing this potential and to addressing the challenges that remain[31].

CONCLUSION

Traumatic brain injury poses significant challenges not only due to its immediate effects but also because of the long-term endocrine dysfunctions that can arise, particularly involving the hypothalamic-pituitary axis. The underdiagnosis of pituitary insufficiency and other related dysfunctions is a major concern, as these conditions significantly affect patient outcomes and quality of life. Neuroimaging has emerged as a critical tool in addressing these challenges, offering detailed insights into the structural and functional status of the hypothalamic-pituitary axis. The use of advanced imaging techniques such as MRI, fMRI, PET, and DTI has enhanced our ability to detect these dysfunctions early, enabling more timely and targeted interventions.

However, the application of neuroimaging in the diagnosis and management of TBI-related endocrine dysfunction is not without its challenges. Variability in imaging protocols, the interpretation of findings, and the integration of imaging data with clinical and laboratory results all require careful consideration. Furthermore, the cost and accessibility of advanced imaging technologies present significant barriers, particularly in resource-limited settings. Ethical considerations also play a critical role in the deployment of these technologies, particularly concerning patient consent, the management of incidental findings, and the potential for overdiagnosis.

Despite these challenges, the future of neuroimaging in the context of TBI-related endocrine dysfunction is promising. Continued advancements in imaging technology, combined with interdisciplinary collaboration and research, hold the potential to further refine our understanding of these complex interactions and to improve patient outcomes. The integration of multimodal imaging approaches and the development of pediatric-specific protocols are areas of particular interest that warrant further exploration.

In conclusion, while significant progress has been made in the use of neuroimaging to detect and manage endocrine dysfunctions following TBI, there is still much to learn. Ongoing research, technological innovation, and clinical collaboration will be essential in advancing the field and ensuring that patients receive the best possible care. The ultimate goal is to integrate these imaging techniques into a comprehensive, patient-centered approach to TBI management that addresses not only the immediate consequences of injury but also the long-term health and well-being of survivors.

REFERENCES

1. Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008;7(8):728-741.

2. Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, Stalla GK, Agha A. Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA. 2007;298(12):1429-1438.

3. Tanriverdi F, Unluhizarci K, Kelestimur F. Pituitary function in subjects with mild traumatic brain injury: a review of literature and proposal of a screening strategy. Pituitary. 2010;13(2):146-153.

4. Agha A, Rogers B, Sherlock M, O'Kelly P, Tormey W, Phillips J, Thompson CJ. Anterior pituitary dysfunction in survivors of traumatic brain injury. J Clin Endocrinol Metab. 2004;89(10):4929-4936.

5. Kelly DF, Gonzalo IT, Cohan P, Berman N, Swerdloff R, Wang C. Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a prospective study. J Neurosurg. 2000;93(5):743-752.

6. Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E. Hypopituitarism. Lancet. 2007;369(9571):1461-1470.

7. Benvenga S, Campennì A, Ruggeri RM, Trimarchi F. Hypopituitarism secondary to head trauma. J Clin Endocrinol Metab. 2000;85(4):1353-1361.

8. Ghigo E, Masel B, Aimaretti G, Léon-Carrión J, Casanueva FF, Dominguez-Morales MR, Elovic EP, Stalla GK, Thompson CJ. Consensus guidelines on screening for hypopituitarism following traumatic brain injury. Brain Inj. 2005;19(9):711-724.

9. Krahulik D, Zapletalová J, Fadrná T, Nádvorníková H, Horáková D, Vybíral S, Frysák Z. Dysfunction of hypothalamic-hypophysial axis after traumatic brain injury in adults. J Neurosurg. 2010;113(3):581-584.

10. Popovic V, Pekic S, Pavlovic D, Maric N, Jasovic-Gasic M, Djurovic B, Doknic M, Medic-Stojanoska M, Dieguez C, Ghigo E, Casanueva FF. Hypopituitarism as a consequence of traumatic brain injury (TBI) and its possible relation with cognitive disabilities and mental distress. J Endocrinol Invest. 2004;27(11):1048-1054.

11. Agha A, Phillips J, Thompson CJ. Hypopituitarism following traumatic brain injury (TBI). Br J Neurosurg. 2007;21(2):210-216.

12. Schneider HJ, Kreitschmann-Andermahr I, Stalla GK. Traumatic brain injury and hypopituitarism. Med Klin Intensivmed Notfmed. 2015;110(9):769-778.

13. Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E. Hypopituitarism in the elderly: current perspectives. Clin Interv Aging. 2007;2(3):453-467.

14. Dubourg J, Messerer M. Pituitary stalk interruption syndrome: towards a clinical, hormonal and radiological classification. Pituitary. 2013;16(3):393-402.

15. Cohan P, Wang C, Futterweit W. Pituitary dysfunction after traumatic brain injury. In: Melmed S, editor. The Pituitary. 4th ed. New York: Academic Press; 2017. p. 661-676.

16. Tan C, Alavi SA, Baldeweg SE, Belli A. Post-traumatic hypopituitarism after TBI: review of current evidence, diagnostic challenges, and emerging controversies. Brain Inj. 2017;31(5):565-579.

17. Kokshoorn NE, Wassenaar MJ, Biermasz NR, Roelfsema F, Smit JW, Pereira AM, Romijn JA. Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. Eur J Endocrinol. 2010;162(1):11-18.

18. Bondanelli M, Ambrosio MR, Zatelli MC, De Marinis L, degli Uberti EC. Hypopituitarism after traumatic brain injury. Eur J Endocrinol. 2005;152(5):679-691.

19. Klose M, Juul A, Struck J, Morgenthaler NG, Kosteljanetz M, Feldt-Rasmussen U. Acute and long-term pituitary insufficiency in traumatic brain injury: a prospective single-centre study. Clin Endocrinol (Oxf). 2007;67(4):598-606.

20. Urban RJ, Harris P, Masel B, Panwar A. Pituitary dysfunction after traumatic brain injury: potential hormone replacement therapy. J Neurotrauma. 2015;32(8):639-648.

21. Cernak I, Savic VJ, Kotur J, Prokic V, Veljovic M, Grbovic D. Characterization of plasma magnesium concentration and oxidative stress following graded traumatic brain injury in humans. J Neurotrauma. 2000;17(1):53-68.

22. Tanriverdi F, Agha A. Diagnosis of hypopituitarism in TBI: what is the gold standard?. Pituitary. 2013;16(3):279-283.

23. Schneider HJ, Stalla GK. Testing for hypopituitarism following traumatic brain injury. Front Neurol. 2012;3:11.

24. Agha A, Sherlock M, Brennan S, O'Connor SA, O'Sullivan E, Rogers B, Tormey W, Phillips J, Thompson CJ. Hypothalamic-pituitary dysfunction after head injury in children and adolescents. J Clin Endocrinol Metab. 2004;89(12):5447-5456.

25. Sesmilo G, Bergada I, Gussinye M, Carrascosa A, Bosch-Castañé J, Ferrer A, Yeste D, Ferrer A, Pinillos R, Albisu MA, Calvo JC. Childhood-onset growth hormone deficiency: etiology, auxological features, and response to growth hormone replacement therapy in a cohort of 131 children. Horm Res. 2000;54(5-6):254-261.

26. Klose M, Juul A, Poulsgaard L, Kosteljanetz M, Brennum J, Jørgensen JO, Feldt-Rasmussen U. Prevalence and predictive factors of post-traumatic hypopituitarism. Clin Endocrinol (Oxf). 2007;67(4):497-504.

27. Aimaretti G, Ambrosio MR, Di Somma C, Fusco A, Cannavò S, Gasperi M, Scaroni C, Del Monte P, De Marinis L, Martino E, Cozzi R, Ghigo E. Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab. 2005;90(11):6085-6092.

28. Cernak I, Merhi M, Jiang J, Bian H, Savic J. Acute and delayed cognitive and neurobehavioral changes in the rat following graded traumatic brain injury. Brain Res. 2001;918(1-2):142-150.

29. Bondanelli M, Ambrosio MR, Zatelli MC, De Marinis L, degli Uberti EC. Neuroendocrine dysfunction in patients surviving severe traumatic brain injury. J Clin Endocrinol Metab. 2007;92(10):4075-4082.

30. Hohl A, Kolbe-Alexandre F, Oliveira EA, Amaro Junior E, Lucato LT. Imaging studies for traumatic brain injury: a narrative review. Crit Ultrasound J. 2015;7(1):9.

31. Matuszak J, Duchen D, Dukas AG, Strainic M, Sullivan P, Agha A. Hypopituitarism in the acute phase after moderate and severe traumatic brain injury in adults: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105(12):dgaa620.